FDA Wants Generic Opioids to Be More Abuse-Deterrent
In the latest step to combat the epidemic of opioid abuse, U.S. officials urge generic drug makers to make changes to opioids.
Diagnosis & Disease Information
Clinicians Respond to New CDC Opioid Guidelines
Mainly supportive of guidelines, but concerns include a lack of evidence underlying some new recommendations.
Older cancer patients often take inappropriate meds
A pharmacist-led comprehensive medication assessment showed a high prevalence of polypharmacy and inappropriate medication use among older patients with cancer.
Nearly one-quarter of children in remission from ALL miss doses of maintenance medication
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
FDA urges opioid prescribers to participate in CME training
Prescribers of extended-release/long-acting opioid analgesics are encouraged to participate in continuing medical education provided by manufacturers of these analgesics.
IOM urges international action to eradicate fake drugs
Falsified and substandard medications pose public health problems around the world, and international action should be taken to combat the phenomenon.
FDA: Draft guidance issued on abuse-deterrent opioids
To assist industry in developing new formulations of opioid drugs with abuse-deterrent properties.
Cancer pain often undertreated, especially among minorities
One-third of outpatients with breast, prostate, colon/rectum, or lung cancer were receiving insufficient pain treatment, particularly minorities.
Nurses report quality of care is better with EHRs
Nurses working in hospitals with basic electronic health records report fewer problems with patient safety and quality-related outcomes.
Unintentional chemotherapy exposure is substantial among oncology nurses
A survey completed by approximately 400 oncology nurses practicing in ambulatory settings indicated that 16.9% had had their skin or eyes exposed to the toxic drugs they deliver.
- Loading...
Loading...
Loading... 
Loading...